Literature DB >> 10705051

In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods.

R E Lewis1, M E Klepser, M A Pfaller.   

Abstract

Two Candida albicans isolates, three non-albicans Candida isolates (Candida glabrata, Candida krusei, and Candida tropicalis), and one Cryptococcus neoformans isolate were evaluated by time-kill methods to characterize the relationship of flucytosine concentrations to antifungal activity and the duration of the post-antifungal effect (PAE). Against Candida and Cryptococcusisolates, flucytosine at concentrations > 1 x MIC exhibited fungistatic (</=99% reduction in CFU) activity over a 24-h time-period. The rate and extent of fungistatic activity of flucytosine against all isolates was generally not increased when 5-FC concentrations exceeded 4 x MIC. A notable PAE was detected for flucytosine against both Candida and Cryptococcus species that persisted 2 to 4 h. These in vitro data suggest that flucytosine is predominately a concentration-independent fungistatic agent at clinically achieved serum concentrations. This pharmacodynamic characteristic coupled with the persistent PAE and the relatively long half-life of flucytosine in humans (> 5 h), suggests lower daily dosing may possible without loss of antifungal efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705051     DOI: 10.1016/s0732-8893(99)00125-x

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 3.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

4.  Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

Authors:  Annemarie E Brouwer; Hendrikus J M van Kan; Elizabeth Johnson; Adul Rajanuwong; Prapit Teparrukkul; Vannaporn Wuthiekanun; Wirongrong Chierakul; Nick Day; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

Review 5.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 7.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 8.  Advances in the treatment of invasive neonatal candidiasis.

Authors:  Lorena Botero-Calderon; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Expert Opin Pharmacother       Date:  2015-04-05       Impact factor: 4.103

Review 9.  Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.

Authors:  Julie Autmizguine; Jeffrey T Guptill; Michael Cohen-Wolkowiez; Daniel K Benjamin; Edmund V Capparelli
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431

10.  Antifungal activity of Cymbopogon winterianus jowitt ex bor against Candida albicans.

Authors:  Wylly Araújo de Oliveira; Fillipe de Oliveira Pereira; Giliara Carol Diniz Gomes de Luna; Igara Oliveira Lima; Paulo Alves Wanderley; Rita Baltazar de Lima; Edeltrudes de Oliveira Lima
Journal:  Braz J Microbiol       Date:  2011-06-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.